Inotiv’s QQ2 2024 results reflect a bifurcated business trajectory: revenue declined 21.5% year over year to 119.0 million, as NHP (non-human primate) demand remained volatile and pricing declined modestly, while the company’s expanding DSA (Discovery and Safety Assessment) services showed resilience and capacity to drive long‑term margin expansion. The quarterly results culminated in a net loss of 48.1 million ($1.86 per diluted share) and an operating loss of 40.4 million, with adjusted EBITDA of 3.1 million (2.6% of revenue). Management has signaled a deliberate shift toward reducing reliance on NHP-related margins, aided by ongoing RMS (research models and services) optimizations, a ramp of DSA value-added offerings, and significant asset/venue closures to lower structural costs. Importantly, Inotiv withdrew fiscal 2024 guidance given uncertainty around NHP demand and pricing, though the company maintains a longer‑term growth plan supported by capacity expansions and a more balanced service mix.
Key takeaways from the quarter and near-term outlook include: (1) DSA activity remained a bright spot with six-month DSA revenue up 3.6% year over year to 91.3 million and non-GAAP DSA operating income of 8.2 million in the quarter; (2) RMS was the primary dragr on revenue, down 30.7% year over year to 72.4 million, reflecting lower NHP volumes and the impact of recent divestitures; (3) NHP pricing declined about 2% in Q2 2024 vs Q1 2024, with peak pricing observed late 2023, signaling a destocking and normalization phase; (4) liquidity remains manageable in the near term with 32.7 million in cash and an orderly asset disposition program (Blackthorn/Haslett closures and Cumberland sale anticipated in Q3) to enhance operating flexibility; (5) The DOJ-related accrual of 26.5 million (subsequently corrected to 19 million) underscores ongoing regulatory/legacy costs that could influence quarterly profitability and liquidity until resolution. Investors should monitor the NHP market re-acceleration, DSA backlog conversion, covenant compliance risk (with ~55 days to cure if needed), and the effectiveness of cost-reduction initiatives in restoring margin trajectory.